Memed Diagnostics Ltd.

Technion Research & Development Foundation Limited

Teva Pharmaceutical Industries Limited

Tel Hashomer Medical Research Infrastructure and Services Ltd.

Kfir Oved

Eran Eden

Roy Navon

Assaf Cohen-Dotan

Olga Boico

Meital Paz

Gali Kronenfeld

James William Luther

Andrea Besana

Barbara Tornaghi

Ilan Ifergan

Noga Salomon

Omer Nahum Katzenelson

Adrian Charles Ian Scott-Murphy

Yana Khalfin

Salit Tzaban

Matthew Fenwick

Ofer Halbreich

Matthew Hou-Pou Yeung

Yoram Reiter

Einav Simon

Amir Gelman

Ellen Bamberger

Matthew Hou Pou Yeung

Roy Noy

Thomas Sanelli Crugnale

Niv Steven Mastboim

Moran Brouk Rudich

Arnon Zangvil

Martin Akerman

Tanya Michelle Gottlieb

Michal Besser

Assaf Cohen-Dota

In a cartridge device for analyzing a body liquid, a first member of the cartridge has two or more wells for performing assays, and a second member of the cartridge has a compartment for holding one or more disposable pipette tips.

Cartridge and system for analyzing body liquid

A method of determining an infection type in a subject is disclosed. The method comprises measuring the concentration of a first determinant selected from the group consisting of the determinants which are set forth in Table 1 and a second determinant selected from the group of the determinants which are set forth in Table 2 in a subject derived sample, wherein the concentration is indicative of the infection type.

Marker combinations for diagnosing infections and methods of use thereof

A method of selecting an exon of an RNA whose expression level is informative with respect to infection type of a subject is disclosed. The method comprises comparing the expression level of the RNA in a sample derived from a bacterially-infected subject and a sample derived from a virally-infected subject at a plurality of exons, wherein the exon that provides a differential expression between the bacterially-infected subject and the virally-infected subject above a predetermined level is selected as the exon of the RNA whose expression is informative with respect to infection type.

Analyzing RNA for diagnosing infection type

A method of determining a management course for treating a subject showing symptoms of a disease is disclosed. The method comprises measuring the TRAIL protein level in a blood sample of the subject, wherein when the TRAIL level is below a predetermined amount, the subject is treated as a high-risk patient.

Methods of prognosis and treatment

A method of analyzing biological data is disclosed. The method comprises obtaining biological data containing at least an expression level of MX dynamin-like GTPase 1 (MX1) and an expression level of C-reactive protein (CRP) in the blood of a subject, calculating a distance between a segment of a curved line and an axis defined by a direction, the distance being calculated at a point over the curved line defined by a coordinate along the direction, and correlating the distance to the presence of, absence of, or likelihood that the subject has, a bacterial infection.

System and method for analysis of biological data

A kit is disclosed for distinguishing between bacterial and viral infections. One of the antibodies of the kit specifically binds to TNF-related apoptosis-inducing ligand (TRAIL) protein and another of the antibodies of the kit specifically binds to Procalcitonin (PCT) protein.

Signatures and determinants for diagnosing infections and methods of use thereof

A method of analyzing biological data containing expression values of a plurality of polypeptides in the blood of a subject. The method comprises: calculating a distance between a segment of a curved line and an axis defined by a direction, the distance being calculated at a point over the curved line defined by a coordinate along the direction. The method further comprises correlating the distance to the presence of, absence of, or likelihood that the subject has, a bacterial infection. The coordinate is defined by a combination of the expression values, wherein at least 90% of the segment is between a lower bound line and an upper bound line.

Computational analysis of biological data using manifold and a hyperplane

Methods of determining infection type are disclosed. In one embodiment, the method comprises measuring the amount of TRAIL and/or IP10 no more than two days from symptom onset.

Early diagnosis of infections

Methods of diagnosing infections are disclosed. In one embodiment, the method comprises measuring the amount of each of the polypeptides TRAIL, CRP, IP10 and at least one additional polypeptide selected from the group consisting of IL-6 and PCT.

Protein signatures for distinguishing between bacterial and viral infections

A method of determining a management course for treating a subject showing symptoms of a disease is disclosed. The method comprises measuring the TRAIL protein level in a blood sample of the subject, wherein when the TRAIL level is above a predetermined amount, the subject is treated as a low-risk patient.

Methods of determining infection type are disclosed. In one embodiment, the method comprises measuring the amount of a determinant which is set forth in Tables 1 or 2 in a sample derived from the subject, wherein said amount is indicative of the infection type.

RNA determinants for distinguishing between bacterial and viral infections

Growing community of inventors

Hof HaCarmel, Israel

Kfir Oved